These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25781230)

  • 1. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
    Wang AL; Elman I; Lowen SB; Blady SJ; Lynch KG; Hyatt JM; O'Brien CP; Langleben DD
    Transl Psychiatry; 2015 Mar; 5(3):e531. PubMed ID: 25781230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients.
    Langleben DD; Ruparel K; Elman I; Loughead JW; Busch EL; Cornish J; Lynch KG; Nuwayser ES; Childress AR; O'Brien CP
    Addict Biol; 2014 Mar; 19(2):262-71. PubMed ID: 22747521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe opioid withdrawal precipitated by Vivitrol®.
    Wightman RS; Nelson LS; Lee JD; Fox LM; Smith SW
    Am J Emerg Med; 2018 Jun; 36(6):1128.e1-1128.e2. PubMed ID: 29605483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
    Gerra G; Fantoma A; Zaimovic A
    J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
    Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
    J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.
    Wang AL; Lowen SB; Elman I; Shi Z; Fairchild VP; Bouril A; Gur RC; Langleben DD
    J Subst Abuse Treat; 2018 Feb; 85():70-77. PubMed ID: 29146290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: an event-related fMRI study.
    Li Q; Wang Y; Zhang Y; Li W; Yang W; Zhu J; Wu N; Chang H; Zheng Y; Qin W; Zhao L; Yuan K; Liu J; Wang W; Tian J
    Brain Res; 2012 Aug; 1469():63-72. PubMed ID: 22759909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
    Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
    Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
    Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
    J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polymorphism of dopamine D2 receptor TaqIA gene is associated with brain response to drug cues in male heroin-dependent individuals during methadone maintenance treatment.
    Li Y; Li Q; Li W; Chen J; Hu F; Liu Y; Wei X; Zhu J; Liu J; Ye J; Shi H; Wang Y; Wang W
    Drug Alcohol Depend; 2019 May; 198():150-157. PubMed ID: 30928885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
    Grinenko AIa; Krupitskiĭ EM; Zvartau EE
    Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: an event-related functional magnetic resonance imaging study.
    Li Q; Li W; Wang H; Wang Y; Zhang Y; Zhu J; Zheng Y; Zhang D; Wang L; Li Y; Yan X; Chang H; Fan M; Li Z; Tian J; Gold MS; Wang W; Liu Y
    Addict Biol; 2015 Sep; 20(5):968-78. PubMed ID: 25214465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.
    Jarvis BP; Holtyn AF; DeFulio A; Dunn KE; Everly JJ; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Addiction; 2017 May; 112(5):830-837. PubMed ID: 27936293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
    Schottenfeld RS; Chawarski MC; Mazlan M
    Lancet; 2008 Jun; 371(9631):2192-200. PubMed ID: 18586174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
    Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
    J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder.
    Shi Z; Jagannathan K; Wang AL; Fairchild VP; Lynch KG; Suh JJ; Childress AR; Langleben DD
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):180-185. PubMed ID: 30690502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
    Hulse GK; Ngo HT; Tait RJ
    Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
    Syed YY; Keating GM
    CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.